News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
182,818 Results
Type
Article (11351)
Company Profile (94)
Press Release (171373)
Section
Business (53145)
Career Advice (133)
Deals (8337)
Drug Delivery (17)
Drug Development (37053)
Employer Resources (18)
FDA (4598)
Job Trends (4741)
News (99677)
Policy (6923)
Tag
Academia (677)
Allergies (60)
Alliances (15378)
Alzheimer's disease (322)
Antibody-drug conjugate (ADC) (79)
Approvals (4611)
Artificial intelligence (75)
Bankruptcy (61)
Best Places to Work (4373)
Biosimilars (45)
Biotechnology (80)
Breast cancer (173)
Cancer (1323)
Career advice (116)
CAR-T (82)
Cell therapy (203)
Clinical research (29920)
Collaboration (309)
Compensation (92)
COVID-19 (1016)
C-suite (64)
Data (846)
Diagnostics (2139)
Earnings (18316)
Events (33001)
Executive appointments (212)
FDA (4918)
Funding (183)
Gene therapy (73)
GLP-1 (150)
Government (868)
Healthcare (5827)
Immunology and inflammation (65)
Infectious disease (1065)
Inflammatory bowel disease (66)
IPO (4281)
Job creations (643)
Job search strategy (109)
Layoffs (143)
Legal (688)
Liver cancer (46)
Lung cancer (201)
Lymphoma (76)
Manufacturing (49)
Medical device (1210)
Medtech (1210)
Mergers & acquisitions (4173)
Metabolic disorders (75)
Neuroscience (452)
NextGen: Class of 2025 (1365)
Non-profit (818)
Northern California (853)
Opinion (44)
Ovarian cancer (47)
Pancreatic cancer (46)
Peanut (44)
People (17233)
Phase I (11135)
Phase II (12951)
Phase III (9445)
Pipeline (346)
Postmarket research (764)
Preclinical (3882)
Prostate cancer (55)
Radiopharmaceuticals (170)
Rare diseases (72)
Real estate (1050)
Regulatory (5988)
Research institute (1048)
Southern California (787)
Startups (1049)
United States (6492)
Vaccines (337)
Date
Today (35)
Last 7 days (250)
Last 30 days (934)
Last 365 days (14197)
2025 (901)
2024 (14356)
2023 (15967)
2022 (19738)
2021 (19748)
2020 (16819)
2019 (12069)
2018 (8964)
2017 (10134)
2016 (9074)
2015 (10049)
2014 (6763)
2013 (4787)
2012 (4962)
2011 (5103)
2010 (4719)
Location
Africa (126)
Asia (13710)
Australia (2135)
California (1889)
Canada (514)
China (223)
Colorado (61)
Connecticut (68)
Delaware (75)
Europe (29839)
Florida (219)
Illinois (130)
Indiana (53)
Japan (63)
Maryland (275)
Massachusetts (1456)
Minnesota (66)
New Jersey (596)
New York (459)
North Carolina (192)
Northern California (853)
Ohio (48)
Pennsylvania (318)
South America (160)
Southern California (787)
Texas (276)
Washington State (207)
182,818 Results for "kineta immuno oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023
Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present at the Oxford Global Immuno US 2023, to be held on October 12-13, 2023 in San Diego, CA.
October 9, 2023
·
1 min read
Press Releases
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
December 12, 2024
·
19 min read
Drug Development
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1
October 2, 2024
·
7 min read
Press Releases
Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
November 8, 2024
·
10 min read
Press Releases
Immuno-Oncology Assays Market Size to Worth USD 10.47 Billion by 2031, Coherent Market Insights
January 9, 2025
·
1 min read
Business
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
October 4, 2024
·
6 min read
BioForest
Kineta to Host Key Opinion Leader Event on KVA12123: VISTA as an Immuno-Oncology Target
Kineta, Inc. announced today it will host a virtual Key Opinion Leader (KOL) event on VISTA as an immuno-oncology target on Monday, March 20, 2023 at 10:00 AM ET.
March 6, 2023
·
6 min read
Business
Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board
Kineta, Inc. announced today the appointment of Myriam Chalabi, M.D. and Evan Ya-Wen Yu, M.D. to the company’s immuno-oncology focused Scientific Advisory Board (SAB).
March 1, 2023
·
7 min read
Press Releases
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
December 12, 2024
·
4 min read
BioForest
Kineta to Present at Upcoming Investor Conferences
Kineta, Inc. announced today that the Company will be attending and presenting at the following upcoming investors conferences.
February 14, 2024
·
1 min read
1 of 18,282
Next
